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Abstract
Purpose Ellagitannins are high molecular weight polyphenols present in high quantities in various food products. They 
are metabolized by human and animal gut microbiota to postbiotic metabolites-urolithins, bioavailable molecules of a low 
molecular weight. Following absorption in the gut, urolithins rapidly undergo phase II metabolism. Thus, to fully evaluate 
the mechanisms of their biological activity, the in vitro studies should be conducted for their phase II conjugates, mainly 
glucuronides. The aim of the study was to comparatively determine the influence of urolithin A, iso-urolithin A, and urolithin 
B together with their respective glucuronides on processes associated with the inflammatory response.
Methods The urolithins obtained by chemical synthesis or isolation from microbiota cultures were tested with their respec-
tive glucuronides isolated from human urine towards modulation of inflammatory response in THP-1-derived macrophages, 
RAW 264.7 macrophages, PBMCs-derived macrophages, and primary neutrophils.
Results Urolithin A was confirmed to be the most active metabolite in terms of LPS-induced inflammatory response inhibi-
tion (TNF-α attenuation, IL-10 induction). The observed strong induction of ERK1/2 phosphorylation has been postulated 
as the mechanism of its action. None of the tested glucuronide conjugates was active in terms of pro-inflammatory TNF-α 
inhibition and anti-inflammatory IL-10 and TGF-β1 induction.
Conclusion Comparative studies of the most abundant urolithins and their phase II conjugates conducted on human and 
murine immune cells unambiguously confirmed urolithin A to be the most active metabolite in terms of inhibition of the 
inflammatory response. Phase II metabolism was shown to result in the loss of urolithins’ pharmacological properties.
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Introduction
Ellagitannins are high-molecular-weight polyphenols pre-
sent in high quantities in various food products and medic-
inal plants. Different health benefits and biological activi-
ties are attributed to these natural products being based 
on the dietary and clinical prospective and retrospective 
studies [1]. The impaired health conditions in which 
ellagitannin-containing products were shown to express 
preventive or curative effects are in particular diseases 
with the inflammatory background such as cardiovascular 
diseases and intestinal inflammations [2–5]. Despite the 
effectiveness of these products has been unambiguously 
confirmed in clinical and epidemiological studies, due to 
the low bioavailability of ellagitannins, this group of com-
pounds cannot be directly considered as factors, which 
trigger the biological effects at the systemic level.
New light on the mechanisms standing behind the 
health benefits of ellagitannins has been put by the studies 
on their metabolism by human gut microbiota, which was 
shown to metabolize ellagitannins of different structures 
and origin to the series of low-molecular-weight postbi-
otic metabolites-urolithins [6]. In contrast to parental mol-
ecules, urolithins are highly lipophilic and thus can easily 
penetrate the biological barriers what was confirmed in 
human and on different animal models [7]. Studies con-
ducted on in vitro and in vivo models have revealed that 
these metabolites are active especially towards inhibition 
of the inflammatory response. In particular, urolithin A 
(UA) was consistently shown to possess strong and struc-
ture-specific anti-inflammatory properties [8–16].
However, according to the pharmacokinetic studies on 
ellagitannin-containing products as well as pure urolithins, 
after absorption in the gut they rapidly undergo metabo-
lism by phase II enzymes, what results in their presence in 
the serum, tissues, and the urine mainly in the form con-
jugated with glucuronic acid [17–21]. These observations 
led to the rise of controversies regarding the translation of 
the in vitro results for non-conjugated urolithins to their 
systemic activity following oral ingestion [7]. Limited 
number of preliminary in vitro studies have shown a loss 
or alterations in the activity, which were associated with 
phase II metabolism of urolithins [9, 22, 23].
In order to fully evaluate the biological activities of 
urolithins with regard to their metabolism and disposi-
tion, the in vitro studies should necessarily acknowledge 
their phase II metabolites, especially glucuronides as 
major conjugates. The low number of bioactivity stud-
ies conducted for urolithin glucuronides is caused by the 
lack of commercially available chemical standards. Dur-
ing our previous studies we have isolated urolithin glu-
curonides, namely iso-urolithin A 3-O-glucuronide (iUA) 
and urolithin B 3-O-glucuronide (GUB), and a mixture of 
two inseparable isomers of urolithin A: 3-O-glucuronide 
and 8-O-glucuronide (GUA) from a urine of a volunteer 
ingesting ellagitannin-rich food products [24]. Using a 
large-scale gut microbiota ex vivo cultures iso-urolithin 
A-a compound characteristic for urolithin metabotype B, 
was obtained [6].
The aim of the study was to comprehensively determine 
the influence of dominating urolithins and their respective 
phase II metabolites on inflammatory response of human 
immune cells focusing not only on their anti-inflammatory 
activity and its molecular mechanisms, but also on their 
potential contribution to the processes associated with 
active resolution of the inflammation. In order to achieve 
a broader view on the comparisons in metabolites activi-
ties, diverse in vitro models were applied including human 
cell line (THP-1 monocytes), murine cell line (RAW 264.7 




Urolithins A and B (UA, UB, respectively) were synthetized 
according to the previously described method [25]. Iso-uro-
lithin A (iUA) was isolated from gut microbiota cultures 
according to [6]. Iso-urolithin A 3-O-glucuronide, mixture 
of urolithin A 3-O-glucuronide and 8-O-glucuronide (GUA) 
and urolithin B 3-O-glucuronide were isolated from human 
urine according to [24]. The identity and purity of com-
pounds were confirmed by 1H NMR and UHPLC-DAD-MS 
methods. The compounds were of > 95% purity. Phorbol 
myristate acetate (PMA) (Sigma-Aldrich GmbH, Steinheim, 
Germany); LPS from E. coli (Invivogen, San Diego, CA, 
USA); parthenolide, roscovitine, and genistein (Sigma-
Aldrich, St. Louis, MO, USA). Urolithins, respective glucu-
ronides and positive controls’ stock solutions were prepared 
in DMSO (Sigma-Aldrich) final concentration of DMSO in 
cell cultures was 0.2% and was used as stimulated and non-
stimulated control throughout the conducted experiments.
THP‑1 monocyte culture and differentiation
THP-1 human monocytic cell line was purchased from 
DSMZ (Braunschweig, Germany). Cells were cultivated at 
37 °C under humidified 5%  CO2 in the RPMI 1640 (Bio-
chrom, Cambridge, UK) medium containing 10% FBS 
(Biochrom) and 2 mM glutamine (Biochrom). In order to 
generate THP-1 macrophages, THP-1 cells were primed 
for 48 h with 12.5 ng/mL PMA followed by 24 h resting. 
The differentiation of the cells was confirmed by changes 
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in morphology, phagocytosis, increased expression of dif-
ferentiation markers CD11b and CD14 and their ability to 
respond to LPS. After 24 h, cells were incubated with uro-
lithins and respective glucuronides at the concentration of 
40 μM for 1 h prior to stimulation with LPS from E. coli 
(10 ng/mL).
RAW 264.7 macrophages culture
The mouse monocyte/macrophage cell line RAW 264.7 
(ATCC TIB 71) was cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Biochrom) supplemented with 
10% FBS (Biochrom), 25 mM HEPES (Biochrom), 50 U 
penicillin/mL and 50 µg streptomycin/mL at 37 °C, 5%  CO2, 
and 95% humidity. Cells were studied between passages 7 
and 30. LPS was used at the concentration of 10 ng/mL for 
macrophage stimulation.
Isolation and cultivation of monocyte/macrophage 
cells
Immediately after collection, 9 mL heparinised blood was 
subjected to a twofold dilution with PBS. Next, the blood 
was layered over 9 mL Ficoll Hypaque density gradient 
(LSM 1077, PAA, Laboratories GmbH, Austria) and cen-
trifuged (1800 rpm, 20 min, 4 °C). The mononuclear cell 
band was removed by the aspiration, washed with cold PBS 
(PAA,), and centrifuged. The cells were suspended in RPMI 
1640 medium with l-glutamine and HEPES (PAA), anti-
biotics: penicillin (100 U/mL), streptomycin (100 μg/mL), 
amphotericin and gentamycin (2.5 μg/mL) (Sigma-Aldrich), 
and autologous serum (20%). To allow the adherence of 
monocytes/macrophages, the peripheral blood mononu-
clear cells suspension was placed in 12-well tissue culture 
plates (2 × 106 per well) and incubated for 2 h at 37 °C under 
humidified 5%  CO2 air. After this time, non-adherent cells 
were removed and washed twice with PBS, whereas adher-
ent cells were cultivated in the same medium and conditions 
for next 7 days. The medium and autologous serum were 
replaced every 2 days [26].
Human primary neutrophils isolation
The buffy coat was prepared from peripheral venous blood 
collected from healthy human donors (20–35 years old) at 
the Warsaw Blood Donation Center. All Donors declared 
that they were non-smokers and did not take any medica-
tions. They were confirmed to be healthy and all tests carried 
out showed values within a normal range. For each experi-
ment buffy coats obtained from three donors were used. 
Neutrophils were isolated using a standard method by dex-
tran sedimentation and centrifugation in a Ficoll Hypaque 
gradient [27]. The purity of neutrophil preparation was over 
97%. After isolation, cells were suspended in HBSS (PAA), 
PBS (PAA) or culture medium (RPMI 1640) and maintained 
at 4 °C before use.
Cell viability
Cytotoxicity of urolithins and respective glucuronides was 
determined using a standard MTT test. After 24 h of incu-
bation of differentiated THP-1 cells with compounds at the 
concentration of 40 μM with or without stimulation with 
LPS (PAA), cells were washed twice with fresh culture 
medium and afterwards 300 μL of the medium containing 
MTT (Carl Roth GmbH, Karlsruhe, Germany) at the con-
centration of 0.5 mg/mL was added. After 1 h of incuba-
tion in 37 °C, the medium was removed, cells were washed 
with fresh medium, and formazan crystals were dissolved in 
300 μL of DMSO (Sigma-Aldrich). Absorbance was meas-
ured at 580 nm.
Phagocytosis assay
Differentiated THP-1 macrophages were treated with com-
pounds (40 µM) for 1 h. The phagocytosis was determined 
using Phagocytosis Assay Kit (IgG FITC) (Cayman Chemi-
cals, Ann Arbor, MI, USA). After the treatment with com-
pounds, 20 µL of FITC labelled beads suspension was added 
to the culture and the cells were incubated at 37 °C for 4 h. 
The level of phagocytosis was determined using flow cytom-
etry (Cytoflex; Beckman Coulter). To distinguish cells which 
have phagocytosed the beads from those binding the beads 
at the surface, a trypan blue quenching solution was added 
before the measurement.
Enzyme‑linked immunosorbent assay (ELISA)
After the stimulation of THP-1 macrophages with LPS, the 
culture media were collected and the levels of TNF-α and 
IL-10 were measured using ELISA kits (BD Biosciences, 
Franklin Lakes, NJ, USA) according to the manufacturer’s 
protocols. Results were represented as fold changes relative 
to the control.
RNA extraction and reverse transcription
After 24-h incubation of THP-1 macrophages with LPS, the 
cell culture media was removed, and the wells were washed 
two times with cold PBS. Cells were scratched to 500 μL 
of RNALater, which was added to each well. The total cel-
lular RNA was extracted using NucleoSpin RNA Clean-up 
(Macherey–Nagel, Düren, Germany) according to the manu-
facturer’s instructions. RNA samples were treated with Pure-
Link DNase (Invitrogen, Carlsbad, CA, USA). The quality 
and quantity of isolated RNA was evaluated using 2100 
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Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). 
Total RNA was reversely transcribed to cDNA using Super-
script III reverse Transcriptase kit (Life Technologies, Carls-
bad, CA, USA) according to the manufacturer’s protocol.
Real‑time PCR analysis
The levels of mRNA expression for TNF-α and TGF-β1 in 
THP-1 macrophages were quantified by Brilliant II SYBR 
Green QPCR Kit (Agilent Technologies, Palo Alto, CA, 
USA) using Aria Mx Real-Time PCR system (Agilent 
Technologies). For the qPCR experiments primers against 
the sequences of human TNF-α (sense: 5′-GGC CTC TGT 
GCC TTC TTT TG-3′, antisense: 5′-CCT CAG CAA TGA 
GTG ACA GT-3′), TGF-β1 (sense: 5′-CGT GGA GCT GTA 
CCA GAA ATA-3′, antisense: 5′-TCC GGT GAC ATC AAA 
AGA TAA-3′), and the housekeeping gene β-actin (ACTB) 
(sense: 5′-TTG CCG ACA GGA TGC AGA AGGA-3′, anti-
sense: 5′-AGG TGG ACA GCG AGG CCA GGAT-3′) were 
purchased from RealTimePrimers (Elkins Park, USA). The 
cycling conditions were 95 °C for 10 min followed by 40 
cycles of denaturing at 95 °C for 15 s and annealing/exten-
sion for 1 min at 60 °C. Relative gene expression was calcu-
lated with the  2−ΔΔCt method, and ACTB was chosen as the 
reference gene. Results were represented as fold expression 
change relative to the control group.
Protein isolation
After 35 min of stimulation THP-1 macrophages with LPS, 
the medium was aspirated, and the cells were washed with 
ice-cold PBS twice. Afterwards, the cells were lysed with 
cOmplete™ Lysis-M (Roche, Basel, Switzerland) contain-
ing Protease and Phosphatase inhibitor cocktail (Roche, 
Basel, Switzerland) and centrifuged at 14,000g for 15 min at 
4 °C. For NFκB p65 nuclear translocation after LPS stimu-
lation the cells were lysed using Mammalian Nuclear and 
Cytoplasmic Protein Extraction Kit (SERVA, Heidelberg, 
Germany). The total protein concentration of the cell and 
nuclear lysates was quantified with BCA protein assay kit 
(Bio-Rad, Hercules, CA, USA) using BSA as a standard. 
After equilibration of protein concentration between the 
samples, the lysates were boiled with 4xLaemmli Sample 
Buffer (Bio-Rad) and stored in − 20 °C.
Western blot analysis
The protein lysates were separated by 10 or 12.5% SDS-
PAGE and transferred to nitrocellulose membrane Amer-
sham Protran (Sigma-Aldrich). The membrane was blocked 
with 5% skimmed milk powder (Sigma-Aldrich) or 5% 
BSA (Sigma-Aldrich) in Tris-buffered saline (Roth GmbH, 
Karlsruhe, Germany) containing 0.1% (v/v) Tween 20 
(SERVA), then incubated overnight at 4 °C with primary 
rabbit monoclonal antibodies: anti-NFκB p65 (Abcam, 
Cambridge, UK), anti-TAK1 (Abcam), anti-p-TAK1, 
Thr184/187 (Cell Signaling Technology, USA), anti-IκBα 
(Abcam), anti-p-IκBα Ser32 (Cell Signaling Technology, 
USA), anti-p38 MAPK (Cell Signaling Technology), anti-
p-p38 MAPK, Thr180/Tyr182 (Cell Signaling Technol-
ogy), anti-SAPK/JNK (Cell Signaling Technology), anti-p-
SAPK/JNK, Thr183/Tyr185 (Cell Signaling Technology), 
anti-ERK1/2 (Cell Signaling Technology), anti-p-ERK1/2, 
Thr202/Tyr204 (Cell Signaling Technology), and anti-beta 
Actin, polyclonal (Abcam). The membranes were washed 
three times and incubated with the secondary antibody at a 
dilution of 1:3000 (v/v). HRP-conjugated goat anti-rabbit 
IgG antibody (Abcam) was used as a secondary antibody. 
The protein bands were detected with SignalFire ECL Rea-
gent (Cell Signaling Technology) and visualized using PXi 
4 Touch (SYNGENE, Frederick, MD, USA). Beta-actin was 
used as a loading control. The protein level was determined 
by normalization to that of beta-actin. Relative expression 
was determined as the ratio of the intensity of the protein 
band to that of the corresponding control band and finally 
represented as fold increase over the control group.
FACS analysis of IL‑10 receptor expression
The expression of IL-10 receptor on the surfaces of mono-
cytes/macrophage cells was determined by flow cytometry 
using FACSCalibur (BD Pharmingen, San Diego, CA, 
USA). Cells were incubated with LPS at a concentration of 
100 ng/mL for 1 h, and they were then incubated with each 
compound for 24 h. All solutions were added to the cells 
on the second day of incubation. Cells then were removed, 
centrifuged (13,000 RPM, 4 °C, 1 min), suspended in PBS 
(100 μL), and incubated with the antibody (PE Rat Anti-
human IL-10, BD Pharmingen, BD Bioscience, USA) for 
20 min at 4 °C. The mean fluorescence intensity in the gated 
cell population was measured (10,000 cells per sample) and 
analyzed by flow cytometry. The results were expressed as 
the percent of cells expressing IL-10 receptor in comparison 
to control cells stimulated by LPS.
Nitrite analysis
Nitrite in RAW 264.7 cell culture supernatants was deter-
mined spectrophotometrically using the Griess reagent 
(0.5% sulfanilic acid, 0.002% N-1-naphtyl-ethylenediamine 
dihydrochloride, 14% glacial acetic acid). Absorbance was 
measured at 550 nm with baseline correction at 650 nm and 
nitrite concentration was determined using sodium nitrite 
as a standard.
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Western blotting for inducible nitric oxide synthase
RAW 264.7 cells were lysed in ice-cold buffer containing 
25 mM monosodium phosphate (pH = 7.4), 75 mM NaCl, 
5 mM EDTA, 1% Triton X-100, and centrifuged at 20,000g 
for 15 min at 4 °C. The cytosolic proteins (12 μg per lane) 
were separated by 12% SDS–polyacrylamide gel electro-
phoresis. Proteins were transferred to nitrocellulose filters 
and then immunoblotted with a rabbit anti-iNOS (obtained 
from Biomol, Hamburg, Germany) or a rabbit anti-actin pol-
yclonal antibody at a 1:2000 dilution. Anti-rabbit alkaline 
phosphatase-conjugated antibody was used as a secondary 
antibody at a dilution of 1:7500. Finally, the blots were incu-
bated with 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 
tetrazolium reagent (Promega) for 10–15 min.
Preparation of nuclear extracts
RAW 264.7 cells (8 × 105) were seeded in 6-well plates. LPS 
and indicated amounts of urolithins were added simultane-
ously to the culture medium for 25 min. Cells were washed 
twice, resuspended in 500 μL lysis buffer (10 mM Tris–HCl 
(pH = 7.5), 2 mM  MgCl2, 10 mM KCl, 0.5 mM dithiothrei-
tol, and 0.6% IGEPAL CA-630), and vortexed for 30 s. 
Nuclei were pelleted by centrifugation at 10 000 g for 2 min 
at 4 °C, resuspended in 30 μL of a buffer containing 20 mM 
Tris–HCl (pH = 7.8), 5 mM  MgCl2, 420 mM NaCl, 0.2 mM 
EGTA, 0.5 mM dithiothreitol, and 25% (v/v) glycerol, vor-
texed for 30 s, and incubated on ice for 15 min. Lysates were 
centrifuged at 20,000g for 5 min at 4 °C. The supernatants 
were kept as aliquots at – 70 °C until analyzed by Western 
blotting as described above. Rabbit anti-NF-κB (p65) pri-
mary antibodies (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) were diluted for optimal signal.
Neutrophil apoptosis
Neutrophils’ viability and apoptosis were determined by stain-
ing with propidium iodide (PI) and Annexin V-FITC using 
Annexin V Apoptosis Detection Kit I (BD Pharmingen, San 
Diego, CA, USA) following the manufacturer’s instructions. 
Neutrophils (2 × 106 per mL) were cultured in a 24-well plate 
in RPMI 1640 medium (as above) in the absence or presence 
investigated compounds at a final concentration 40 µM added 
1 h before the stimulation with LPS (100 ng/mL). Cells were 
collected, centrifuged (2000 rpm; 10 min; 4 °C), and resus-
pended in 100 µl of binding buffer. Next 5 μL of Annexin and 
5 μL of propidium iodide solutions were added. The mixture 
was vortexed and incubated for 15 min at room temperature in 
the darkness. Then, 400 µl of cold binding buffer was added 
and the cells were analyzed by flow cytometry (FACSCali-
bur) within 1 h after labeling and data from 10,000 events 
were recorded. Before each experiment compensation (using 
untreated cells, cells with Annexin V and cells with iodide pro-
pidium) was performed and quadrants have been set. Roscovi-
tine at a concentration of 40 µM was used as a positive control.
Impact on β‑glucuronidase release (azurophilic 
granules)
After isolation, neutrophils were resuspended in HBSS 
(6 × 105 cells/mL) with urolithins and respective glucuron-
ides at the concentration of 40 μM, primed with cytochalasin 
B (10 μM) for 5 min and then stimulated with f-MLP (1 μM) 
for 10 min. The neutrophils were centrifuged (2000 rpm; 
10 min; 4 °C). The amount of released β-glucuronidase in 
supernatants was determined using a human β-glucuronidase 
ELISA Kit (Wuhan Fine Biological Technology Co., Ltd, 
Wuhan, China) according to the manufacturer’s instructions.
Impact on specific granules release
After isolation, neutrophils were resuspended in HBSS 
(6 × 105 cells/mL) with urolithins and respective glucuron-
ides at the concentration of 40 μM, primed with cytochalasin 
B (10 μM) for 5 min and then stimulated with f-MLP (1 μM) 
for 10 min. The neutrophils were centrifuged (12,000g; 15 s; 
4 °C), washed once with cold HBSS and stained with anti-
CD66b-FITC antibody (BD Pharmingen, San Diego, CA, 
USA), incubated 30 min. in darkness, centrifuged (12,000g; 
15 s; 4 °C), washed with HBSS with 0.01% BSA, centri-
fuged, resuspended in HBSS with 0.01% BSA and analyzed 
using flow cytometry (FACSCalibur) within 0.5 h after 
labelling, and data from 10,000 events were recorded. Gen-
istein at the concentration of 40 μM was used as a positive 
control.
Statistical analysis
Results of at least three independent experiments performed 
in triplicate are shown as mean values ± SD. Statistical sig-
nificance of differences between means was determined by 
one-way ANOVA. For comparison of results with the con-
trol group, Dunnett’s post hoc test was used. To compare 
the differences between the inhibitory activities of com-
pounds, Tukey’s post hoc test was performed. Results with 
p value < 0.05 were considered statistically significant. All 
analyses were performed using Statistica 13 software.
Results
None of the tested compounds exhibited cytotoxic effect 
on THP-1 macrophages (MTT test, Fig. S1) and on human 
primary neutrophils (propidium iodide staining followed by 
FACS analysis, Fig. S2).
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The first and most abundant cytokine produced by mac-
rophages following inflammatory stimuli is TNF-α. Strong 
inhibition of TNF-α production was observed for UA, 3 and 
6 h after LPS stimulation (by 44.3 ± 8.1% and 24.8 ± 7.7% 
respectively). In contrast, its isomer-iUA after 6 h caused 
significant increase in TNF-α level by 34.6 ± 9.8% (Fig. 1). 
The incubation of cells with respective glucuronide conju-
gates GUA and GiUA did not result in any changes in this 
cytokine production. The qPCR determination of mRNA has 
shown that the decrease in the TNF-α protein levels were 
strictly dependent on the modification of the expression of 
mRNA for TNF-α (Fig. 2). The inhibition of TNF-α produc-
tion was compared with positive control-parthenolide (inhib-
itor of NFκB pathway), which at the concentration of 5 μM 
decreased the level of TNF-α by 66.8 ± 5.5% after 3 h and by 
58.9 ± 8.8% after 6 h (Figs. 1, 2). The inhibitory activity of 
UA towards TNF-α production was additionally confirmed 
on human primary macrophages. UA at the concentration of 
40 μM showed much stronger inhibition (91.7 ± 5.5%) than 
on THP-1 macrophages. In contrast to the observations con-
ducted on THP-1 macrophages, where iUA induced TNF-α 
production, in primary cells it inhibited the production of 
Fig. 1  Effects of tested urolithins and respective glucuronides at the 
concentration of 40  μM on LPS-induced TNF-α and IL-10 produc-
tion. PMA-differentiated THP-1 cells were preincubated for 1 h with 
iso-urolithin A, urolithin A and B (iUA, UA, UB) and their respective 
glucuronides (GiUA, GUA, GUB) at the concentration of 40 μM and 
stimulated with LPS (10  ng/mL). Statistical significance: *p < 0.05, 
**p < 0.001 decrease versus stimulated control (Dunnettʼs post hoc 
test); #p < 0.05, ##p < 0.001 increase versus stimulated control; LPS—
stimulated control; NST—non-stimulated control. Parth-parthenolide 
at the concentration of 5  μM (positive control). Data are expressed 
as mean ± SD of three separate experiments performed in triplicate. 
Mean ± SD and p values are provided in Supplementary material 
Table S3
1963European Journal of Nutrition (2021) 60:1957–1972 
1 3
Fig. 2  Effects of tested urolithins and respective glucuronides at 
the concentration of 40  μM on LPS induced TNF-α and TGF-β1 
mRNA expression in THP-1 macrophages. PMA-differentiated 
THP-1 cells were preincubated for 1  h with iso-urolithin A, uro-
lithin A and B (iUA, UA, UB) and their respective glucuronides 
(GiUA, GUA, GUB) at the concentration of 40  μM and stimulated 
with LPS (10 ng/mL) for 24 h. Real-time RT-PCR analysis was per-
formed as described in Sect. “Materials and methods”. Changes in 
mRNA expression were normalized to β-actin. *p < 0.05, **p < 0.001 
decrease versus stimulated control (Dunnettʼs post hoc test); 
#p < 0.05, #p < 0.001—statistically significant increase versus stimu-
lated control; LPS—stimulated control; NST—non-stimulated con-
trol. Parth-parthenolide at the concentration of 5  μM (positive con-
trol). Data are expressed as mean ± SD of three separate experiments 
performed in duplicate. Mean ± SD and p values are provided in Sup-
plementary material Table S4
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this cytokine by 54.4 ± 3.4% (Fig. 3). Similarly, as on THP-1 
cell line model, respective glucuronides remained inactive 
towards suppression of the inflammatory response of pri-
mary macrophages.
Macrophages are known to be responsible for the reso-
lution of inflammation by release of anti-inflammatory 
cytokines such as IL-10, which inhibits the proinflammatory 
cytokine production (such as TNF-α and IL-1β). They also 
secrete TGF-β1, which has a broad range of anti-inflam-
matory functions. TGF-β1 can induce neutrophil apopto-
sis, inhibit T-cell proliferation, and induce monocyte dif-
ferentiation to macrophages and is a potent suppressor of 
the proinflammatory monocyte activation [28]. UA and UB 
were stimulating the expression of TGF-β1 in THP-1 mac-
rophages by 60.0 ± 25.0% and 35.0 ± 16.7% respectively. As 
in previous experiments, the corresponding glucuronides 
remained inactive (Fig. 2). The stimulation of IL-10 pro-
duction was only observed for iUA by 41.4 ± 21.6% (Fig. 1). 
Studies on IL-10 receptor surface expression have shown its 
strong increase in primary macrophages incubated with UA 
and UB (Fig. 4).
Another crucial step in the resolution of inflammation is 
the phagocytosis of neutrophils and the cellular debris by 
macrophages [28]. In order to evaluate the potential influ-
ence of urolithins on this process we monitored their impact 
on phagocytosis of FITC-labelled IgG coated beads. The 
phagocytosis of beads by THP-1 macrophages was shown to 
be time dependent (Fig. S3). In order to evaluate the changes 
in the phagocytosis induced by the tested compounds, the 
determination of their activity was conducted 4 h after incu-
bation,; however, neither urolithin aglycones nor glucuron-
ides were active in the tested model (Fig. S3).
The studies on the molecular mechanism of the cytokine 
release inhibition/stimulation have shown that all of the 
compounds, including urolithin glucuronides influenced the 
NFκB pathway and the inhibition took place between IκBα 
degradation and p65 nuclear translocation. The inhibitory 
activity was apparently much more pronounced for GUA 
and GUB than for respective free urolithins. The inhibition 
was not as strong as observed for parthenolide at the con-
centration of 5 μM, which has almost completely attenu-
ated the entry of p65 to the nucleus (Fig. 5). Much stronger 
inhibition of NFκB p65 nuclear translocation to the nucleus 
observed for GiUA, GUA and GUB (Fig. 5b) was,, however, 
not congruent with their lack of influence on TNF-α, IL-10 
and TGF-β1 production and does not explain outstanding 
activity of UA on TNF-α production. Thus, the influence on 
MAP kinases phosphorylation was examined. Neither uro-
lithins, nor their glucuronides influenced the LPS-induced 
p38 and SAPK/JNK phosphorylation. Significant changes 
were observed in the ERK1/2 phosphorylation, which was 
strongly stimulated by UA and slightly by iUA (Fig. 5).
In order to bridge the current research with our previous 
studies on RAW 264.7 murine macrophages [13] the com-
parative examination of UA and GUA was additionally con-
ducted using this cell model. Incubation of stimulated RAW 
264.7 macrophages with increasing amounts of UA was 
associated with a concentration-dependent reduction of the 
Fig. 3  Effects of tested urolithins and respective glucuronides at the 
concentration of 40 μM on LPS-induced TNF-α. PBMCs were incu-
bated with iso-urolithin A, urolithin A and B (iUA, UA, UB) and 
their respective glucuronides (GiUA, GUA, GUB) at the concentra-
tion of 40 μM and stimulated with LPS (100 ng/mL). Statistical sig-
nificance: *p < 0.05, **p < 0.001 decrease versus stimulated control 
(Dunnettʼs post hoc test); #p < 0.05, #p < 0.001—statistically signifi-
cant increase versus stimulated control; LPS—stimulated control; 
NST—non-stimulated control. Data are expressed as mean ± SD of 
three separate experiments performed in triplicate. Mean ± SD and p 
values are provided in Supplementary material Table S5
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NO production. The extent of inhibition was 62.5 ± 10.3% 
for 20 µM UA, and 99.6 ± 2.4% for 40 µM UA. GUA did 
not inhibit inducible nitric oxide synthesis. UA, but not 
GUA, was shown to decrease iNOS protein expression in a 
concentration-dependent manner what was associated with 
significant reduction of p65 nuclear translocation (Fig. 6).
Neutrophils are another type of immune cells contrib-
uting to the inflammatory response. They release granules 
containing various factors being cytotoxic for pathogenic 
microorganisms such as proteolytic enzymes and reactive 
oxygen species, which are responsible for tissue injury 
during persistent inflammation [28]. Studies conducted on 
human primary neutrophils isolated from peripheral venous 
blood have shown that UA and UB are able to inhibit the 
release of azurophilic granules (determined as the amount of 
excreted β-glucuronidase) (Fig. 7), while none of the tested 
compounds influenced the specific granule release which 
was monitored as the surface expression of CD66b (Fig. 
S4). The results were compared with the activity of positive 
control-genistein at the concentration of 40 μM, which is a 
broad specificity tyrosine kinase inhibitor known to inhibit 
neutrophil degranulation [29].
A key component of resolution of inflammation is ensur-
ing that recruited neutrophils are cleared from the site of 
injury. Such clearance mechanisms prevent the inappropriate 
activation and the release of neutrophil microbial defense 
mechanisms and consequently host tissue injury. The pro-
cesses leading to the removal of neutrophils include apopto-
sis and local efferocytosis by macrophages [28]. The studies 
on apoptosis have shown no cytotoxic activity on human 
primary neutrophils for any of the compounds and none of 
them was able to induce neutrophil apoptosis, neither in 
LPS-stimulated nor in non-stimulated cells. Roscovitine-
CDK inhibitor at the concentration of 40 μM was used as a 
positive control (Fig. S2).
Discussion
In the present study, the comparative examinations of in vitro 
anti-inflammatory activities of urolithins and their phase II 
metabolites were conducted on human immune cells. The 
examinations were performed for the most abundant uro-
lithins characteristic of metabotypes A and B [7]: iUA, UA 
and UB as well as their respective glucuronide conjugates. 
Since recent data suggest that phenotype-based classification 
of macrophages in vivo is an oversimplification as pheno-
types are very specific to their microenvironment [30], the 
Fig. 4  Effects of tested urolithins and respective glucuronides at the 
concentration of 40  μM on IL-10 receptor expression. PBMC mac-
rophages were incubated with iso-urolithin A, urolithin A and B 
(iUA, UA, UB) and their respective glucuronides (GiUA, GUA, 
GUB) at the concentration of 40  μM and stimulated with LPS 
(100 ng/mL). Presented data are representative for three independent 
experiments performed with cells isolated from independent donors
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comparative studies of compound’s activity were conducted 
on broad spectrum of macrophages origin: THP-1 human 
cell line-derived macrophages, RAW 264.7 murine mac-
rophages and human primary macrophages. It was clearly 
confirmed that UA is the most active metabolite not only in 
terms of the inhibition of human immune cells’ inflamma-
tory response induced by TLR4 receptor stimulation, but 
also towards stimulation of production of cytokines respon-
sible for resolution of inflammation-IL-10 and TGF-β1. 
These results are congruent with previous studies conducted 
on THP-1 macrophages for UA, UB and urolithin C showing 
the strongest inhibition of UA on TNF-α production [12] 
as well as inhibition of TNF-α-induced MMP-9 production 
[31]. The mechanism of anti-inflammatory activity of UA 
and UB based on inhibition of NFκB translocation to the 
nucleus and involvement of MAPK phosphorylation in this 
process was for the first time determined by Gonzalez-Sar-
rias et al. on colon fibroblasts stimulated with IL-1β [16]. 
The same compounds were also tested on murine RAW 
264.7 macrophages indicating exceptional activity of UA 
towards their inflammatory response, which was also dem-
onstrated to depend on inhibition of NFκB p65 nuclear trans-
location [13]. The inhibition of NFκB pathway by UA was 
later confirmed on various murine cell models-macrophages 
and microglial cells. UA inhibited LPS-triggered produc-
tion of NO, ROS and pro-inflammatory proteins in murine 
J774.1 macrophages, what depended on elevated autophagic 
flux, which in turn blocked NFκB p65 translocation to the 
Fig. 5  Effects of tested urolithins and respective glucuronides at the 
concentration of 40  μM on LPS-induced NF-κB and MAPK path-
way activation in THP-1 macrophages. PMA-differentiated THP-1 
cells were preincubated for 1  h with iso-urolithin A, urolithin A 
and B (iUA, UA, UB) and their respective glucuronides (GiUA, 
GUA, GUB) at the concentration of 40 μM and stimulated with LPS 
(10 ng/mL) for 35 min. Western blotting analysis was performed as 
described in “Materials and methods”. The chart B represents the 
changes in p65 protein levels in nuclear fractions normalized to p65 
protein levels in cytosolic fractions. Chart C represents the changes 
in phospho-ERK1/2 normalized to total ERK1/2. Statistical sig-
nificance: *p < 0.05, **p < 0.001 decrease versus stimulated control 
(Dunnettʼs post hoc test); #p < 0.05, #p < 0.001—statistically signifi-
cant increase versus stimulated control; LPS—stimulated control; 
NST—non-stimulated control. Parth-parthenolide at the concentra-
tion of 5 μM (positive control). Densitometric analysis was performed 
using ImageJ software. Mean ± SD and p values are provided in Sup-
plementary material Table  S6. All presented data are representative 
for three independent experiments
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nucleus. No influence on IκBα degradation was observed; 
thus the point of action of UA was located between the 
release from IκB and the nuclear translocation of p65 [32]. 
Further studies on LPS-stimulated RAW 264.7 macrophages 
indicated UA to inhibit pro-inflammatory mediators’ pro-
duction by suppressing NOX-derived reactive oxygen 
species-mediated PI3-K/Akt/NF-κB and JNK/AP-1 and 
p38 signaling pathways. On this cell model UA was shown 
to inhibit degradation of IκBα; however, no influence on 
ERK1/2 phosphorylation was observed [10]. Studies on 
BV2 microglia cells confirmed UA to inhibit pro-inflam-
matory cytokines (TNF-α and IL-6) what was caused by 
the inhibition of p65 NFκB phosphorylation and acetyla-
tion [33]. UB also inhibited the production of NO and 
pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and 
increased anti-inflammatory IL-10 in LPS-stimulated BV2 
cells. UB suppressed NF-κB activity by inhibiting the phos-
phorylation and degradation of IκBα and the suppression 
of AP-1 activity in LPS-stimulated BV2 cells. In addition, 
UB suppressed the phosphorylation of JNK, ERK, and Akt, 
and enhanced the phosphorylation of AMPK. It was inactive 
in terms of p38 phosphorylation [34]. Nitrite analysis and 
qRT-PCR suggested that UA and UB reduced NO levels 
and suppressed mRNA levels of pro-inflammatory genes 
of TNF-α, IL-6, IL-1β, iNOS and COX-2 in LPS-treated 
BV2 microglia. Western blot revealed that tested urolithins 
decreased phosphorylation levels of Erk1/2, p38 MAPK and 
Akt, prevented the IκB-α phosphorylation and degradation 
Fig. 6  Effects of UA and GUA at the concentration of 40 and 20 μM 
on LPS-induced NO production, iNOS expression and NF-κB p65 
nuclear translocation in RAW 264.7 macrophages. Inhibition of nitric 
oxide production by UA was statistically significant (p < 0.001, deter-
mined by ANOVA followed by Student’s t tests for unpaired data) 
at all concentrations tested. The increase of nitric oxide synthesis 
between GUA and UA was statistically highly significant (p < 0.001). 
Data were expressed as mean ± SD. Data shown are representative for 
three independent experiments
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and inhibited NF-κB p65 subunit phosphorylation and its 
nuclear translocation [15]. The anti-inflammatory activity 
of UA was also shown on different murine in vivo models. 
Anti-inflammatory properties of a pomegranate extract and 
its metabolite urolithin-A were demonstrated in a colitis rat 
model [11]. In vivo anti-inflammatory and antioxidant prop-
erties of ellagitannin metabolite urolithin A were also dem-
onstrated on carrageenan-induced paw edema model in mice 
[8]. Orally applied UA was shown to inhibit p65 NFκB and 
p38 phosphorylation on in vivo neuroinflammation mouse 
model [35]. Treatment with UA attenuated colitis in animal 
models by restoring barrier dysfunction in addition to anti-
inflammatory activities [36]. The anti-inflammatory activity 
of UA was previously shown on human chondrocytes. UA 
was inhibiting IL-1β-induced expression of iNOS, COX-2, 
TNF-α and IL-6, what depended on attenuated p65 nuclear 
translocation [37].
The hereby determined influence of UA on the inflam-
matory response of human macrophages (primary and cell 
line) unambiguously confirms previously established effects 
on murine in vitro and in vivo models. However, some dis-
crepancies regarding the mechanism of action have to be 
addressed. Similarly, as in the previously published research, 
UA was indeed shown to attenuate the NF-κB p65 nuclear 
translocation; however, the effect was not exceptional in 
the comparison to its isomer iUA and was even weaker 
than for its glucuronide conjugates, which had no effect 
on TNF-α production. As in studies conducted by Boakye 
et al. although inhibition of NF-κB p65 translocation was 
observed, the degradation of IκBα was not prevented by any 
of the compounds. In contrast to earlier studies, no inhibi-
tion of SAPK/JNK and p38 phosphorylation was observed, 
while very strong induction of ERK1/2 phosphorylation for 
UA was determined. The induction of ERK1/2 phosphoryla-
tion was previously reported to serve as an anti-inflamma-
tory signal that suppresses expression of NFκB-dependent 
inflammatory genes by inhibiting IKK activity. The increase 
in the level of pERK1/2 can exert the anti-inflammatory 
response and can contribute to the observed inhibition of 
TNF-α production [38]. The observed inconsistency in the 
mechanism of action of UA could be due to the fact that 
so far almost only murine in vitro and in vivo models were 
applied for its anti-inflammatory activity studies. It is known 
that the effects on signaling pathways in humans differ from 
those in mice when similar or even identical mutations are 
compared within the proteins involved. Because NF-κB and 
MAPKs pathways are involved in the infection control and 
the hygienic conditions as well as pathogens impinging on 
Fig. 7  Effects of tested urolithins and respective glucuronides at the 
concentration of 40  μM on f-MLP-induced β-glucuronidase release 
from human primary neutrophhils. After isolation, neutrophils were 
resuspended in HBSS with iso-urolithin A, urolithin A and B (iUA, 
UA, UB) and their respective glucuronides (GiUA, GUA, GUB) 
at the concentration of 40 μM primed with cytochalasin B (10 μM) 
for 5 min and then stimulated with f-MLP (1 μM) for 10 min. Sta-
tistical significance: *p < 0.05, **p < 0.001 decrease versus stimulated 
control (Dunnettʼs post hoc test); fMLP—stimulated control; NST—
non-stimulated control. Genist-genistein at the concentration of 
40 μM (positive control). Data were expressed as mean ± SD of three 
separate experiments performed with cells isolated from independ-
ent donors. Mean ± SD and p values are provided in Supplementary 
material Table S7
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the lives of primates and rodents are different, the evolution 
adapted their functions according to the precise requirements 
of the two orders [39]. What is more, the data regarding 
the metabolism of ellagitannins to urolithins in rodents are 
showing either low urolithin production yield in the com-
parison to other mammals or domination of other type of 
metabolites, namely nasutins [24, 40–43].
Previous comparative study of UA and GUA regarding 
impact on the inflammatory response was conducted on 
human aortic endothelial cells stimulated with TNF-α. It has 
shown the decrease in the IL-8 production only for UA, PAI 
levels and monocyte adhesion attenuation only for GUA, 
while both compounds decreased the levels of CCL-2 [9]. 
Recent studies on human primary leukocytes have shown 
that UA and iUA are potent to reduce the formation of the 
5-LOX/COX-2 pathway products  (HKE2 and  HKD2) through 
the attenuation of COX-2 and PGE2, while urolithin C was 
shown to reduce 5-HETE and LTB4 via inhibition of 5-LOX. 
The respective glucuronide and sulfate conjugates of UA 
and iUA were inactive [44]. In the present study no activ-
ity towards the production of pro- and anti-inflammatory 
cytokines was observed for phase II conjugates of urolithins. 
Despite significant inhibition of NFκB p65 translocation was 
unambiguously determined for GiUA, GUA and GUB, its 
consequences were not seen at the tested cytokine mRNA 
expression and protein level. Thus, we hypothesize, that in 
THP-1 macrophages the stimulation of ERK1/2 phosphoryl-
ation, which was determined for UA could play a role in its 
exceptional activity towards inhibition of TNF-α production. 
The loss of activity of urolithins due to phase II metabolism 
is also consistent with previous studies conducted on breast 
cancer and colon cancer cell lines. Glucuronidation was 
shown to decrease the anti-proliferative effects of UA and 
UB on colon cancer cell lines. Phase-II metabolism in HT-29 
cells was a mechanism of cancer resistance against urolith-
ins due to their conversion to glucuronide conjugates that 
exerted lower antiproliferative activity [23]. iUA, UA and 
UB exerted antiproliferative and antiestrogenic activities, 
but both their glucuronide and sulfate conjugates expressed 
much lower or no activities. In addition, the tested aglycones 
underwent phase II metabolism in breast cancer cell lines 
[22].
Urolithins are claimed to be actively glucuronidated in 
the large intestinal enterocytes before entering the blood-
stream as their phase II metabolites. In consequence, the 
major metabolites present in the bloodstream and tissues 
are mainly urolithin glucuronide conjugates, whose maxi-
mal concentrations in the human plasma reach up to 35 μM 
for GUA, 0.745 μM for GiUA, and 7.3 μM for GUB. Sig-
nificantly higher concentrations of the conjugates were 
detected in urine after the repeated consumption of ellagi-
tannin-containing food products: 927–5330 μM for GUA 
and 550–6185 μM for GUB [7]. Taking into consideration 
the strong inhibitory activity of urolithins [in particular UA 
(which has been so far unambiguously confirmed on murine 
and human cell lines)], towards the inflammatory response 
of immune cells, the development of accelerated detoxify-
ing mechanisms for these xenobiotics already in the gut wall 
is justified. Especially if the fact of urolithins production 
from commonly consumed food products is considered, 
what without sufficient phase II metabolism could negatively 
affect immune cells homeostasis in the healthy organism. As 
shown in current studies, the glucuronidation process is fully 
effective, as it leads to loss of impact on the inflammatory 
response of human immune cells.
The anti-inflammatory activity of urolithin aglycones 
applied at the concentration of 40 μM can be relevant to 
their potent interaction with the intestinal epithelium, 
as the levels of urolithins in feces were shown to reach 
up to 37–7180 μg/g of UA, 36–207 μg/g of iUA μM and 
13–1894 μg/g of UB [7]. However, due to phase II metabo-
lism already taking place in enterocytes, following absorp-
tion they are present in serum mainly as glucuronide con-
jugates GUA, GiUA, GUB at the concentrations, which 
in conducted study were unequivocally shown to be inac-
tive. Despite applied concentration of urolithin aglycones 
in conducted in vitro studies is beyond the levels detected 
in serum following ingestion of ellagitannin-containing 
products, it needs to be noted that tissue distribution and 
metabolic disposition havenot been yet fully established, 
especially in the case of tissues with ongoing inflammation. 
In the previous studies we have shown that urolithin glu-
curonides are cleaved by human β-glucuronidase, which is 
released by human neutrophils from azurophilic granules 
upon stimulation of formyl peptide receptor-1 [24]. Based 
on the obtained results we hypothesized that the selective 
activation of urolithin glucuronides by β-glucuronidase pre-
sent at high concentrations at the inflammation site could 
only locally increase the concentration of biologically active 
urolithin aglycones. Taking into consideration very low solu-
bility of urolithins in aqueous environment, this process can 
lead to their precipitation in inflamed tissues resulting in 
significantly elevated concentrations of free aglycones at 
the inflammation site. Our hypothesis of on-site activation 
of urolithin glucuronides was partially confirmed in further 
in vivo studies conducted on rats with LPS-induced systemic 
inflammation [45].
Conclusions
For the first time, comparative studies of the most abundant 
urolithins and their phase II conjugates were conducted on 
human immune cells. UA was unambiguously confirmed to 
be the most active metabolite in terms of inhibition of the 
inflammatory response both in THP-1 cell line as well as in 
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primary macrophages. It was not only shown to attenuate 
NFκB p65 nuclear translocation, what is fully congruent 
with previous studies, but was also to significantly stimu-
late ERK1/2 phosphorylation, what stands in contradiction 
with previous in vitro and in vivo examinations conducted 
on murine models. The determined moderate discrepan-
cies in the mechanism of action could be the consequence 
of the differences in mechanisms of immune response 
between murine and human cells, what should be consid-
ered while designing further in vitro and in vivo studies. 
Phase II metabolism of urolithins was clearly shown to cause 
their deactivation. Urolithin glucuronides were not active 
towards any of the tested signaling protein expression or 
production; however, they were clearly shown to inhibit 
NFκB p65 nuclear translocation. In order to elucidate what 
are the consequences of this attenuation at the cytokine and 
chemokine level, further studies including their broader 
array are necessary.
Author contributions JPP designed the research. AB, AF, TM, AK, 
JPP, conducted the experiments. SG, TM, JZ, MFM, JPP contributed 
new reagents and analytic tools. JPP performed the data analysis and 
wrote the manuscript.
Funding The project was financially supported by a Polish Ministry of 
Science and Higher Education research Grant, Iuventus Plus [IP2015 
062274]. JPP was financially supported by Alexander von Humboldt 
Foundation.
Compliance with ethical standards 
Conflict of interest The Authors declare no conflict of interest.
Availability of data and material All data is provided in Supplementary 
material.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Garcia-Munoz C, Vaillant F (2014) Metabolic fate of ellagitan-
nins: implications for health, and research perspectives for innova-
tive functional foods. Crit Rev Food Sci Nutr 54(12):1584–1598. 
https ://doi.org/10.1080/10408 398.2011.64464 3
 2. Larrosa M, Garcia-Conesa MT, Espin JC, Tomas-Barberan 
FA (2010) Ellagitannins, ellagic acid and vascular health. 
Mol Aspects Med 31(6):513–539. https ://doi.org/10.1016/j.
mam.2010.09.005
 3. Biasi F, Astegiano M, Maina M, Leonarduzzi G, Poli G (2011) 
Polyphenol supplementation as a complementary medicinal 
approach to treating inflammatory bowel disease. Curr Med Chem 
18(31):4851–4865. https ://doi.org/10.2174/09298 67117 97535 263
 4. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, 
Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-
Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, 
Sorli JV, Martinez JA, Fito M, Gea A, Hernan MA, Martinez-
Gonzalez MA, Investigators PS (2018) Primary prevention of 
cardiovascular disease with a mediterranean diet supplemented 
with extra-virgin olive oil or nuts. N Engl J Med 378(25):e34. 
https ://doi.org/10.1056/NEJMo a1800 389
 5. Huber R, Ditfurth AV, Amann F, Guthlin C, Rostock M, Trittler 
R, Kummerer K, Merfort I (2007) Tormentil for active ulcerative 
colitis: an open-label, dose-escalating study. J Clin Gastroenterol 
41(9):834–838. https ://doi.org/10.1097/MCG.0b013 e3180 4b217 
3
 6. Piwowarski JP, Granica S, Stefanska J, Kiss AK (2016) Differ-
ences in metabolism of ellagitannins by human gut microbiota 
ex  vivo cultures. J Nat Prod 79(12):3022–3030. https ://doi.
org/10.1021/acs.jnatp rod.6b006 02
 7. Tomas-Barberan FA, Gonzalez-Sarrias A, Garcia-Villalba R, 
Nunez-Sanchez MA, Selma MV, Garcia-Conesa MT, Espin JC 
(2017) Urolithins, the rescue of “old” metabolites to understand a 
“new” concept: Metabotypes as a nexus among phenolic metabo-
lism, microbiota dysbiosis, and host health status. Mol Nutr Food 
Res 61 (1). doi: https ://doi.org/10.1002/mnfr.20150 0901
 8. Ishimoto H, Shibata M, Myojin Y, Ito H, Sugimoto Y, Tai 
A, Hatano T (2011) In  vivo anti-inflammatory and antioxi-
dant properties of ellagitannin metabolite urolithin A. Bioorg 
Med Chem Lett 21(19):5901–5904. https ://doi.org/10.1016/j.
bmcl.2011.07.086
 9. Gimenez-Bastida JA, Gonzalez-Sarrias A, Larrosa M, Tomas-
Barberan F, Espin JC, Garcia-Conesa MT (2012) Ellagitannin 
metabolites, urolithin A glucuronide and its aglycone urolithin 
A, ameliorate TNF-alpha-induced inflammation and associated 
molecular markers in human aortic endothelial cells. Mol Nutr 
Food Res 56(5):784–796. https ://doi.org/10.1002/mnfr.20110 0677
 10. Komatsu W, Kishi H, Yagasaki K, Ohhira S (2018) Urolithin A 
attenuates pro-inflammatory mediator production by suppress-
ing PI3-K/Akt/NF-kappaB and JNK/AP-1 signaling pathways in 
lipopolysaccharide-stimulated RAW264 macrophages: possible 
involvement of NADPH oxidase-derived reactive oxygen species. 
Eur J Pharmacol 833:411–424. https ://doi.org/10.1016/j.ejpha 
r.2018.06.023
 11. Larrosa M, Gonzalez-Sarrias A, Yanez-Gascon MJ, Selma MV, 
Azorin-Ortuno M, Toti S, Tomas-Barberan F, Dolara P, Espin 
JC (2010) Anti-inflammatory properties of a pomegranate extract 
and its metabolite urolithin-A in a colitis rat model and the effect 
of colon inflammation on phenolic metabolism. J Nutr Biochem 
21(8):717–725. https ://doi.org/10.1016/j.jnutb io.2009.04.012
 12. Piwowarski JP, Granica S, Zwierzynska M, Stefanska J, Schopohl 
P, Melzig MF, Kiss AK (2014) Role of human gut microbiota 
metabolism in the anti-inflammatory effect of traditionally used 
ellagitannin-rich plant materials. J Ethnopharmacol 155(1):801–
809. https ://doi.org/10.1016/j.jep.2014.06.032
 13. Piwowarski JP, Kiss AK, Granica S, Moeslinger T (2015) Urolith-
ins, gut microbiota-derived metabolites of ellagitannins, inhibit 
LPS-induced inflammation in RAW 264.7 murine macrophages. 
Mol Nutr Food Res 59(11):2168–2177. https ://doi.org/10.1002/
mnfr.20150 0264
 14. Piwowarski JP, Granica S, Kiss AK (2014) Influence of gut 
microbiota-derived ellagitannins’ metabolites urolithins on 
1971European Journal of Nutrition (2021) 60:1957–1972 
1 3
pro-inflammatory activities of human neutrophils. Planta Med 
80(11):887–895. https ://doi.org/10.1055/s-0034-13686 15
 15. Xu J, Yuan C, Wang G, Luo J, Ma H, Xu L, Mu Y, Li Y, Seeram 
NP, Huang X, Li L (2018) Urolithins attenuate LPS-induced neu-
roinflammation in BV2Microglia via MAPK, Akt, and NF-kappaB 
signaling pathways. J Agric Food Chem 66(3):571–580. https ://
doi.org/10.1021/acs.jafc.7b032 85
 16. Gonzalez-Sarrias A, Larrosa M, Tomas-Barberan FA, Dolara P, 
Espin JC (2010) NF-kappaB-dependent anti-inflammatory activity 
of urolithins, gut microbiota ellagic acid-derived metabolites, in 
human colonic fibroblasts. Br J Nutr 104(4):503–512. https ://doi.
org/10.1017/S0007 11451 00008 26
 17. Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson 
M, Aebischer P, Auwerx J, Singh A, Rinsch C (2019) The 
mitophagy activator urolithin A is safe and induces a molecu-
lar signature of improved mitochondrial and cellular health in 
humans. Nat Metab 1:595–603
 18. Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, 
Tome-Carneiro J, Zafrilla P, Mulero J, Tomas-Barberan FA, 
Espin JC (2015) Identifying the limits for ellagic acid bioavail-
ability: a crossover pharmacokinetic study in healthy volun-
teers after consumption of pomegranate extracts. J Funct Foods 
19:225–235. https ://doi.org/10.1016/j.jff.2015.09.019
 19. Cerda B, Soto C, Albaladejo MD, Martinez P, Sanchez-
Gascon F, Tomas-Barberan F, Espin JC (2006) Pomegranate 
juice supplementation in chronic obstructive pulmonary dis-
ease: a 5-week randomized, double-blind, placebo-controlled 
trial. Eur J Clin Nutr 60(2):245–253. https ://doi.org/10.1038/
sj.ejcn.16023 09
 20. Pfundstein B, Haubner R, Wurtele G, Gehres N, Ulrich CM, Owen 
RW (2014) Pilot walnut intervention study of urolithin bioavail-
ability in human volunteers. J Agric Food Chem 62(42):10264–
10273. https ://doi.org/10.1021/jf504 0652
 21. Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, 
Gomez-Sanchez MB, Garcia-Talavera NV, Gil-Izquierdo A, 
Sanchez-Alvarez C, Fontana-Compiano LO, Morga-Egea JP, 
Pastor-Quirante FA, Martinez-Diaz F, Tomas-Barberan FA, 
Espin JC (2010) Occurrence of urolithins, gut microbiota ellagic 
acid metabolites and proliferation markers expression response 
in the human prostate gland upon consumption of walnuts and 
pomegranate juice. Mol Nutr Food Res 54(3):311–322. https ://
doi.org/10.1002/mnfr.20090 0152
 22. Avila-Galvez MA, Espin JC, Gonzalez-Sarrias A (2018) Physi-
ological relevance of the antiproliferative and estrogenic effects 
of dietary polyphenol aglycones versus their phase-II metabo-
lites on breast cancer cells: a call of caution. J Agric Food Chem 
66(32):8547–8555. https ://doi.org/10.1021/acs.jafc.8b031 00
 23. Gonzalez-Sarrias A, Gimenez-Bastida JA, Nunez-Sanchez MA, 
Larrosa M, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC 
(2014) Phase-II metabolism limits the antiproliferative activity of 
urolithins in human colon cancer cells. Eur J Nutr 53(3):853–864. 
https ://doi.org/10.1007/s0039 4-013-0589-4
 24. Piwowarski JP, Stanislawska I, Granica S, Stefanska J, Kiss AK 
(2017) Phase II conjugates of urolithins isolated from human 
urine and potential role of beta-glucuronidases in their disposi-
tion. Drug Metab Dispos 45(6):657–665. https ://doi.org/10.1124/
dmd.117.07520 0
 25. Bialonska D, Kasimsetty SG, Khan SI, Ferreira D (2009) Urolith-
ins, intestinal microbial metabolites of Pomegranate ellagitannins, 
exhibit potent antioxidant activity in a cell-based assay. J Agric 
Food Chem 57(21):10181–10186. https ://doi.org/10.1021/jf902 
5794
 26. Zapolska-Downar D, Siennicka A, Chelstowski K, Widecka K, 
Goracy I, Halasa M, Machalinski B, Naruszewicz M (2006) Is 
there an association between angiotensin-converting enzyme 
gene polymorphism and functional activation of monocytes and 
macrophage in young patients with essential hypertension? J 
Hypertens 24(8):1565–1573. https ://doi.org/10.1097/01.hjh.00002 
39292 .32883 .38
 27. Boyum A (1968) A one-stage procedure for isolation of granulo-
cytes and lymphocytes from human blood—general sedimentation 
properties of white blood cells in a 1 G gravity field. Scand J Clin 
Lab Inv S 21:51–000
 28. Headland SE, Norling LV (2015) The resolution of inflammation: 
principles and challenges. Semin Immunol 27(3):149–160. https 
://doi.org/10.1016/j.smim.2015.03.014
 29. Mocsai A, Jakus Z, Vantus T, Berton G, Lowell CA, Ligeti E 
(2000) Kinase pathways in chemoattractant-induced degranulation 
of neutrophils: the role of p38 mitogen-activated protein kinase 
activated by Src family kinases. J Immunol 164(8):4321–4331. 
https ://doi.org/10.4049/jimmu nol.164.8.4321
 30. Aldo PB, Craveiro V, Guller S, Mor G (2013) Effect of culture 
conditions on the phenotype of THP-1 monocyte cell line. Am J 
Reprod Immunol 70(1):80–86. https ://doi.org/10.1111/aji.12129 
 31. Dell’agli M, Galli GV, Bulgari M, Basilico N, Romeo S, Bhat-
tacharya D, Taramelli D, Bosisio E (2010) Ellagitannins of 
the fruit rind of pomegranate (Punica granatum) antago-
nize in  vitro the host inflammatory response mechanisms 
involved in the onset of malaria. Malar J 9:208. https ://doi.
org/10.1186/1475-2875-9-208
 32. Boakye YD, Groyer L (1862) Heiss EH (2018) an increased 
autophagic flux contributes to the anti-inflammatory potential 
of urolithin A in macrophages. Biochim Biophys Acta Gen Subj 
1:61–70. https ://doi.org/10.1016/j.bbage n.2017.10.006
 33. Velagapudi R, Lepiarz I, El-Bakoush A, Katola FO, Bhatia H, 
Fiebich BL, Olajide OA (2019) Induction of autophagy and acti-
vation of SIRT-1 deacetylation mechanisms mediate neuroprotec-
tion by the pomegranate metabolite urolithin A in BV2 microglia 
and differentiated 3D human neural progenitor cells. Mol Nutr 
Food Res 63(10):e1801237. https ://doi.org/10.1002/mnfr.20180 
1237
 34. Lee G, Park JS, Lee EJ, Ahn JH, Kim HS (2019) Anti-inflam-
matory and antioxidant mechanisms of urolithin B in activated 
microglia. Phytomedicine 55:50–57. https ://doi.org/10.1016/j.
phyme d.2018.06.032
 35. Gong Z, Huang J, Xu B, Ou Z, Zhang L, Lin X, Ye X, Kong X, 
Long D, Sun X, He X, Xu L, Li Q, Xuan A (2019) Urolithin A 
attenuates memory impairment and neuroinflammation in APP/
PS1 mice. J Neuroinflammation 16(1):62. https ://doi.org/10.1186/
s1297 4-019-1450-3
 36. Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde 
B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, 
Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, 
Dryden GW, Alatassi H, Zhang HG, Haribabu B, Vemula PK, Jala 
VR (2019) Enhancement of the gut barrier integrity by a micro-
bial metabolite through the Nrf2 pathway. Nat Commun 10(1):89. 
https ://doi.org/10.1038/s4146 7-018-07859 -7
 37. Fu X, Gong LF, Wu YF, Lin Z, Jiang BJ, Wu L, Yu KH (2019) 
Urolithin A targets the PI3K/Akt/NF-kappaB pathways and pre-
vents IL-1beta-induced inflammatory response in human osteoar-
thritis: in vitro and in vivo studies. Food Funct 10(9):6135–6146. 
https ://doi.org/10.1039/c9fo0 1332f 
 38. Maeng YS, Min JK, Kim JH, Yamagishi A, Mochizuki N, Kwon 
JY, Park YW, Kim YM, Kwon YG (2006) ERK is an anti-inflam-
matory signal that suppresses expression of NF-kappaB-depend-
ent inflammatory genes by inhibiting IKK activity in endothelial 
cells. Cell Signal 18(7):994–1005. https ://doi.org/10.1016/j.cells 
ig.2005.08.007
 39. Zhang Q, Lenardo MJ, Baltimore D (2017) 30 Years of NF-
kappaB: a blossoming of relevance to human pathobiology. Cell 
168(1–2):37–57. https ://doi.org/10.1016/j.cell.2016.12.012
1972 European Journal of Nutrition (2021) 60:1957–1972
1 3
 40. Gonzalez-Barrio R, Truchado P, Ito H, Espin JC, Tomas-Barberan 
FA (2011) UV and MS identification of urolithins and nasutins, 
the bioavailable metabolites of ellagitannins and ellagic acid in 
different mammals. J Agric Food Chem 59(4):1152–1162. https 
://doi.org/10.1021/jf103 894m
 41. Cerda B, Ceron JJ, Tomas-Barberan FA, Espin JC (2003) 
Repeated oral administration of high doses of the pomegranate 
ellagitannin punicalagin to rats for 37 days is not toxic. J Agric 
Food Chem 51(11):3493–3501. https ://doi.org/10.1021/jf020 842c
 42. Milala J, Kosmala M, Karlinska E, Juskiewicz J, Zdunczyk Z, 
Fotschki B (2017) Ellagitannins from strawberries with different 
degrees of polymerization showed different metabolism through 
gastrointestinal tract of rats. J Agric Food Chem 65(49):10738–
10748. https ://doi.org/10.1021/acs.jafc.7b041 20
 43. Jurgonski A, Juskiewicz J, Fotschki B, Kolodziejczyk K, Milala J, 
Kosmala M, Grzelak-Blaszczyk K, Markiewicz L (2017) Metabo-
lism of strawberry mono- and dimeric ellagitannins in rats fed a 
diet containing fructo-oligosaccharides. Eur J Nutr 56(2):853–
864. https ://doi.org/10.1007/s0039 4-015-1133-5
 44. Gimenez-Bastida JA, Gonzalez-Sarrias A, Espin JC, Schneider 
C (2020) Inhibition of 5-lipoxygenase-derived leukotrienes and 
hemiketals as a novel anti-inflammatory mechanism of urolith-
ins. Mol Nutr Food Res 64(11):e2000129. https ://doi.org/10.1002/
mnfr.20200 0129
 45. Avila-Galvez MA, Gimenez-Bastida JA, Gonzalez-Sarrias A, 
Espin JC (2019) Tissue deconjugation of urolithin A glucuro-
nide to free urolithin A in systemic inflammation. Food Funct 
10(6):3135–3141. https ://doi.org/10.1039/c9fo0 0298g 
